Dihexa: The Synaptogenic Peptide and Its Research Limits

Dihexa is an experimental compound derived from angiotensin IV that, in rodent and cell studies, strongly promotes the formation of new synapses, the connections between brain cells. That makes it scientifically interesting for memory research, but Dihexa has no published controlled human trials, is not approved in any country, and acts on a growth pathway linked to cancer. For now, it belongs in the laboratory, not in a medicine cabinet.

What is Dihexa?

Dihexa (also known in research papers as PNB-0408) is a modified, very small peptide built from angiotensin IV, a fragment of the angiotensin hormone system. Researchers at Washington State University developed it while studying how angiotensin IV affects learning and memory. Two features made it stand out:

• It appears to cross the blood-brain barrier, which most peptides do not.
• It is orally active in animal studies, again unusual for a peptide.

Those properties, plus striking results in rodent studies, are why Dihexa became popular in online "nootropic" circles. Popularity, however, is not evidence.

How Dihexa works: the HGF/c-Met pathway

Dihexa's main proposed mechanism is enhancing the activity of hepatocyte growth factor (HGF) at its receptor, c-Met. Despite its name, HGF acts in many tissues, including the brain, where c-Met signaling supports neuron survival, growth of dendritic spines (the small protrusions where synapses form) and synaptic plasticity.

In laboratory studies, Dihexa:

• Increased dendritic spine formation and new synapses in cultured rat hippocampal neurons
• Improved performance in rats with chemically induced memory impairment
• Improved learning tasks in aged rats

You will often see Dihexa described as "ten million times more potent than BDNF." That figure comes from a specific cell-culture assay of spine formation. It does not mean Dihexa is ten million times more effective at improving memory in people, and it should not be read that way.

What the Dihexa evidence does and does not show

Here is an honest summary of where the science stands:

• Cell and rodent data: present and consistent. The mechanism has been described in peer-reviewed pharmacology papers, and rat models show improved cognitive performance.
• Human trials of Dihexa: none published. I am not aware of any completed, peer-reviewed controlled trial of Dihexa in humans for any condition.
• Related compounds have struggled. A different HGF/c-Met-modulating drug from the same research lineage was tested in people with Alzheimer's disease and did not meet its primary endpoint in a mid-to-late-stage trial in 2024. That does not settle the question for Dihexa, but it is a reminder that a strong rodent signal does not guarantee a human benefit.
• Long-term safety: unknown. There are no human data on what happens with months or years of use.

The cancer question

The most important safety concern with Dihexa follows directly from how it works. The HGF/c-Met pathway is a growth and survival signal. When it is overactive, it is implicated in the growth, invasion and spread of several cancers, including some gastric, lung and liver cancers. Drugs that block c-Met are used in oncology for exactly that reason.

A compound designed to amplify c-Met signaling therefore raises a reasonable theoretical concern: could it encourage the growth of an existing, undiagnosed tumor? There are no human data to answer this either way. In my view, that uncertainty is a strong reason not to use Dihexa outside a properly designed clinical trial, and an absolute reason to avoid it in anyone with a personal history of cancer.

Regulatory status

What to do instead if you are worried about memory or focus

People ask about Dihexa because they are noticing real problems: forgetfulness, slower thinking or trouble concentrating. Those concerns deserve a real workup. As an internist, these are the things I look at first:

• Sleep, including screening for sleep apnea, one of the most common and treatable causes of poor concentration (sleep architecture and hormonal restoration covers this in more depth)
• Mood and stress, since depression and anxiety commonly present as cognitive complaints
• Medications, especially sedating or anticholinergic drugs, which can impair memory
• Labs, including thyroid function, vitamin B12, glucose control, kidney and liver function, and a blood count
• Vascular risk factors, such as blood pressure, cholesterol and diabetes, which affect long-term brain health
• Hearing and vision, which affect attention and cognitive load
• Lifestyle foundations: regular aerobic and resistance exercise, alcohol reduction and social engagement, all of which have better human evidence for brain health than any nootropic

When symptoms are progressive or affect daily function, formal cognitive testing and neurology referral are appropriate.

Where Dihexa fits among cognitive peptides

Dihexa is often grouped with other compounds marketed for brain health. Their evidence differs a great deal. Cerebrolysin is approved in roughly 50 countries (not the US) and has human trial data in stroke and dementia. Selank and Semax are approved in Russia and have mostly Russian-language clinical literature. Dihexa sits at the earliest end of this spectrum, with no approval and no published human trials. You can compare their profiles in our peptide library.

At Laeeq M.D., I am glad to talk through any compound a patient has read about. Often the most useful outcome is a clear explanation of what is known, what is not, and which well-supported steps will help most.

Sources

• Benoist CC, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. Journal of Pharmacology and Experimental Therapeutics, 2014. https://pmc.ncbi.nlm.nih.gov/articles/PMC4201273/
• Dihexa: Cognitive Vitality Report. Alzheimer's Drug Discovery Foundation. https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Dihexa_1.pdf
• FDA Advisory Committee Endorses Compounding of Certain Peptides. Holland & Knight, 2026. https://www.hklaw.com/en/insights/publications/2026/08/fda-advisory-committee-endorses-compounding-of-certain-peptides

Book a Consultation

If memory, focus or brain health is on your mind, a thorough evaluation is the right first step. You can book a consultation for a 60-minute visit with Dr. Laeeq, virtually or in Reston, VA, to review your history, medications and labs and build an evidence-based plan.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.